西班牙抗富亮氨酸胶质瘤失活蛋白1(LGI1)脑炎治疗后的神经、精神及睡眠评估:一项前瞻性队列研究
这项西班牙21家医院的前瞻性队列研究纳入24例抗LGI1脑炎患者和18名健康对照,在初始免疫治疗后1年内进行3次神经精神及视频多导睡眠图评估。研究发现,尽管接受了免疫治疗,多数患者仍存在认知、精神及睡眠结构异常,且这些异常可促使追加免疫治疗并改善;但12个月时仍有65%患者存在认知缺陷。
要点
- 抗LGI1脑炎患者初始免疫治疗后1年内,83%存在认知缺陷,83%有精神症状,58%失眠,50%快速眼动睡眠行为障碍。
- 视频多导睡眠图显示,79%患者存在睡眠结构破坏,63%有过度片段性肌阵挛,38%有肌纤维颤搐放电。
- 12个月时65%患者持续存在认知缺陷,与未使用利妥昔单抗、REM睡眠期无肌张力及血清LGI1抗体阳性相关。
核心结论
- 抗LGI1脑炎患者初始免疫治疗后第一年及以后,未被识别的持续临床和视频多导睡眠图异常常见,这些异常可治疗,可能影响认知结局。
研究设计与样本
- 前瞻性队列研究,从西班牙21家医院招募患者,纳入24例抗LGI1脑炎患者和18名年龄性别匹配的健康对照,患者接受3次访视(基线、6个月、12个月)。
主要发现
- 基线时(距初始免疫治疗中位88天),全部24例患者至少有一种症状,20例(83%)有认知缺陷,20例(83%)有精神症状,14例(58%)失眠,12例(50%)快速眼动睡眠行为障碍,9例(38%)面臂肌张力障碍性发作,7例(29%)局灶性发作。
- 视频多导睡眠图显示,19例(79%)患者存在睡眠结构破坏而健康对照无(p=0.013);15例(63%)患者和4例(22%)健康对照有过度片段性肌阵挛(p=0.039);9例(38%)患者有肌纤维颤搐放电而健康对照无(p=0.0051)。
- 这些临床和视频多导睡眠图特征促使15例(63%)患者接受额外免疫治疗,所有15例均改善。
- 12个月时,20例患者中13例(65%)持续存在认知缺陷;持续认知缺陷与基线前未使用利妥昔单抗(OR 4.0,95%CI 1.5-10.7;p=0.0015)、基线REM睡眠期无肌张力(OR 2.2,95%CI 1.2-4.2;p=0.043)及基线血清LGI1抗体阳性(OR 11.0,95%CI 1.1-106.4;p=0.038)相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis is an autoimmune disorder that can be treated with immunotherapy, but the symptoms that remain after treatment have not been well described. We aimed to characterise the clinical features of patients with anti-LGI1 encephalitis for 1 year starting within the first year after initial immunotherapy. METHODS: For this prospective cohort study, we recruited patients with anti-LGI1 encephalitis as soon as possible after they had received conventional immunotherapy for initial symptoms; patients were recruited from 21 hospitals in Spain. Patients were excluded if they had an interval of more than 1 year since initial immunotherapy, had pre-existing neurodegenerative or psychiatric disorders, or were unable to travel to Hospital Clínic de Barcelona (Barcelona, Spain). Patients visited Hospital Clínic de Barcelona on three occasions-the first at study entry (visit 1), the second 6 months later (visit 2), and the third 12 months after the initial visit (visit 3). They underwent neuropsychiatric and videopolysomnography assessments at each visit. Healthy participants who were matched for age and sex and recruited from Hospital Clínic de Barcelona underwent the same investigations at study entry and at 12 months. Cross-sectional comparisons of clinical features between groups were done with conditional logistic regression, and binary logistic regression was used to assess associations between cognitive outcomes at 12 months and clinical features before initial immunotherapy and at study entry. FINDINGS: Between May 1, 2019, and Sept 30, 2022, 42 participants agreed to be included in this study. 24 (57%) participants had anti-LGI1 encephalitis (mean age 63 years [SD 12]; 13 [54%] were female and 11 [46%] were male) and 18 (43%) were healthy individuals (mean age 62 years [10]; 11 [61%] were female and seven [39%] were male). At visit 1 (median 88 days [IQR 67-155] from initiation of immunotherapy), all 24 patients had one or more symptoms; 20 (83%) patients had cognitive deficits, 20 (83%) had psychiatric symptoms, 14 (58%) had insomnia, 12 (50%) had rapid eye movement (REM)-sleep behaviour disorder, nine (38%) had faciobrachial dystonic seizures, and seven (29%) had focal onset seizures. Faciobrachial dystonic seizures were unnoticed in four (17%) of 24 patients and focal onset seizures were unnoticed in five (21%) patients. At visit 1, videopolysomnography showed that 19 (79%) patients, but no healthy participants, had disrupted sleep structure (p=0·013); 15 (63%) patients and four (22%) healthy participants had excessive fragmentary myoclonus (p=0·039), and nine (38%) patients, but no healthy participants, had myokymic discharges (p=0·0051). These clinical and videopolysomnographic features led to additional immunotherapy in 15 (63%) of 24 patients, which resulted in improvement of these features in all 15 individuals. However, at visit 3, 13 (65%) of 20 patients continued to have cognitive deficits. Persistent cognitive deficits at visit 3 were associated with no use of rituximab before visit 1 (odds ratio [OR] 4·0, 95% CI 1·5-10·7; p=0·0015), REM sleep without atonia at visit 1 (2·2, 1·2-4·2; p=0·043), and presence of LGI1 antibodies in serum at visit 1 (11·0, 1·1-106·4; p=0·038). INTERPRETATION: Unsuspected but ongoing clinical and videopolysomnography alterations are common in patients with anti-LGI1 encephalitis during the first year or more after initial immunotherapy. Recognising these alterations is important as they are treatable, can be used as outcome measures in clinical trials, and might influence cognitive outcome. FUNDING: Fundació La Caixa.
引用
- Muñoz-Lopetegi A, Guasp M, Prades L, et al. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study. Lancet Neurol. 2024. PMID: 38365378. doi:10.1016/S1474-4422(23)00463-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。